Bas Ludoph, Sonia Yan, Kelly Wang and Hannah Wang co-authored this post with Matt Furlow.
China has become the world’s second largest pharmaceutical market (the US is No. 1), but novel drugs contribute to just a small fraction of that market. While there's great potential in China for novel drugs—especially those developed to treat cancer—it has historically been a challenging market due to a difficult drug approval process, stringent market access policies and a complex healthcare ecosystem. Those factors have shifted over time and made China more amenable to external investments, particularly for novel oncology therapies.Read More